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N-aryl-oxazolidinones is a prominent family of antimicrobials used for treating infections caused by
clinically prevalent Gram-positive bacteria. Recently, boron-containing compounds have displayed
intriguing potential in the antibiotic discovery setting. Herein, we report the unprecedented introduction
of a boron-containing moiety such as an aryl boronic acid in the external region of the oxazolidinone
structure via a chemoselective acyl coupling reaction. As a result, we accessed a series of analogues with
a distal aryl boronic pharmacophore on the oxazolidinone scaffold. We identified that a peripheric linear
conformation coupled with freedom of rotation and no further substitution on the external aryl boronic
ring, an amido linkage with hydrogen bonding character, in addition to a para-relative disposition be-
tween boronic group and linker, are the optimal combination of structural features in this series for
antimicrobial activity. In comparison to linezolid, the analogue comprising all those features, compound
20b, displayed levels of antimicrobial activity augmented by an eight-fold to a thirty-two-fold against a
panel of Gram-positive strains, and a near one hundred-fold against Escherichia coli JW5503, a Gram-
negative mutant strain with a defective efflux capability.
© 2020 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The evaluation of novel pharmacophores in known and/-or
unprecedented drug-like scaffolds is key to explore broad areas of
the chemical space and unveil drug candidates with uncharted
therapeutic profiles [1]. This approach is of utmost relevance in the
antibiotic discovery setting [2], amidst the pre-pandemic global
emergence of antimicrobial resistance (AMR) [3], that combined
with a complex confluence of economic [4], regulatory [5], and
societal factors drastically restricts the development of novel first-
in-class antimicrobial drugs [6]. Such threatening pharmaceutical
scenario is aggravated by a gap in knowledge not only on the mo-
lecular basis underlying novel AMR mechanisms but also on the
delicate balance of interplaying physicochemical properties that
translates into optimal intracellular accumulation andPerea-Buceta).
r Masson SAS. This is an open accantimicrobial activity [7]. Consequently, there is an urge-pressing
need to expand the molecular space covered by antimicrobial dis-
covery programs. In this manner, we may strengthen our under-
standing of the structure-activity relationships (SAR) and predictive
guidelines that may lead to the optimal design of broad-spectrum
antimicrobials[2,6,8].
N-aryl-oxazolidinones (NAOs), such as linezolid (LZD) 1,
constitute the last family of discovered first-in-class synthetic an-
tibiotics (Scheme 1b), and are used as the last resort therapy in
major infections caused by multidrug-drug resistant (MDR) Gram-
positive bacteria (GPB) [9]. The NAOs family is distinguished by a
unique binding mode to the A-site pocket of the 50S subunit of
bacterial ribosomes at the peptidyl transferase centre (PTC), that
inhibits the formation of the 70S initiation ribosomal complex, an
essential intermediate for protein synthesis and bacterial growth
[10,11]. Furthermore, three characteristics define NAOs as a privi-
leged platform for antimicrobial development. Firstly, a compre-
hensively studied SAR clearly establishes that an acetamide group
or hydroxyl hydrogen-bonding donor at the C-5 side chain of the
oxazolidinone core ring, and at least one fluorine atom in the meta-ess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Scheme 1. Unprecedented oxazolidinones featuring an aryl boronic acid ring in their
peripheral west section.
C.D. Cruz, P. Wrigstedt, K. Moslova et al. European Journal of Medicinal Chemistry 211 (2021) 113002position of the adjacent aryl ring B (Scheme 1a), are the structural
elements essential for antimicrobial activity [12]. Secondly, the
prevalence of AMR against NAOs has been comparatively lower
compared to other antibiotics, although the appearance of generic
forms of NAOs already in the market (Scheme 1b) is expected to
promote AMR cases [13]. Thirdly, their structure is relatively simple
in relation to other antibiotics, enabling facile access to libraries of
candidate molecules covering broader areas of SAR chemical space
with less time and resources[14].
The majority of recent pharmaceutical research on NAOs has
been focused on the introduction of a diverse array of polar sub-
stituents and heterocycles on their peripheral west section to raise
additional biological interactions outside the cavity of the PTC
[9,15].
Conversely, we aimed to explore the effects that a Lewis acid
pharmacophore such a boronic acid could impart in the antimi-
crobial activity of NAOs. These pharmacophores are known to
possess high specificity to bind diol residues near the active site of
key enzymes in protein synthesis and gene translation, such as
leucyl-t-RNA synthethases (LeuRS) or serine proteases [16].
Furthermore, boron-containing compounds have been shown
recently to possess intriguing potential in the antimicrobial dis-
covery setting as novel b-lactamase inhibitors [17], quorum sensing
modulators [18], or as prospective inhibitors of the NorA efflux
pump in MDR Staphylococcus aureus strains [19]. In this context, we
herein disclose our findings on the synthesis and antimicrobial
evaluation of a novel series of NAO analogues equipped with distal
aryl boronic functional groups on their external section (Scheme
1c).2. Results and discussion
2.1. Chemistry
We deemed that the east section of radezolid 3 (Scheme 1b)
could be the most convenient synthetic platform to pursue the
introduction of distal aryl boronic pharmacophores in an oxazoli-
dinone scaffold. To that end, the presence in 3 of a para-substituted
aryl ring C with a protic functional group such as an amine provides2
a synthetic handle for further functionalization and assures a
modular character for the synthetic approach. Additionally, rade-
zolid is a second generation NAO antimicrobial with augmented
pharmaceutical properties such as improved potency, activity
against many LZD-resistant bacterial strains and even moderate
activity against some Gram-negative bacteria (GNB) such as Hae-
mophilus influenza and Moraxella catarrhalis [20]. To begin our
studies, we selected the synthetic route reported by Frost and co-
workers to prepare advanced intermediate 6 (Scheme 2) which
they used as racemic synthon for the total syntheses of LZD, tedi-
zolid and rivaroxaban.[21a] Although this route does not allow to
control the configuration at the C-5 stereocentre of the central
oxazolidinone ring, we considered that its relative efficiency, scal-
ability, and modular character was quite convenient to swiftly ac-
cess a series of aryl boronic analogues 10a-f with different
substituents on the terminal aryl boronic ring.
With the advanced intermediate 6 in hand, the targeted series
of analogues 10a-f were prepared through a straightforward two-
step sequence comprising a Suzuki-Miyaura reaction [21b], fol-
lowed by esterification of the resulting alcohol with a series of 4-
carboxyphenylboronic acids 9a-f. In this task, we were pleased to
observe that a combination of 1-ethyl-3-(3-dimethylamino
propyl) carbodiimide hydrochloride (EDC$HCl) and 4-
dimethylaminopyridine (DMAP) furnished the corresponding
aryl boronic analogues 10a-f in good yield. Indeed, careful tuning
of the reaction conditions and experimental procedure allowed
us to supersede protodeboronation events, that are well-known
to occur in acylation reactions using phenyl boronic as coupling
agents [22], as well as the formation of trimeric boroxine anhy-
dride species that are known to generate by dehydration of the
parent boronic acid [23]. This is unambiguously confirmed by
NMR spectroscopy and HRMS (see Appendix A). Surprisingly, the
reaction tolerated well several phenyl boronic acids with ortho-
and meta- electron-poor substituents such as Cl- and F-, as
coupling partners, albeit delivered complex mixtures when the
boronic acid featured an electron-rich methoxy substituent. For
the syntheses of chiral aryl boronic derivatives we implemented
the route adapted by Stoltz’s group of the initial Upjohn &
Pharmacia synthetic approach [24], that allows constructing the
oxazolidinone core with full stereocontrol at C-5 in three steps
from (S)-epichlorohydrin by using a para-chlorophenyl auxiliary
to mask the amine group at the terminal alkyl chain (Scheme 2).
In our hands, the subsequent cleavage of that auxiliary in in-
termediate 12 and release of the free amino group was achieved in
a straightforward and robust manner via transimination reaction
with an excess of isobutylamine [25]. Next, acetylation of the free
amino group followed by electrophilic iodination of the aryl ring B
with NIS on TFA furnished intermediate 13, that was then used as
common building block to synthesize the series of chiral oxazoli-
dinones with a distal aryl boronic fragment comprised in this study.
For this task, the prior two-step sequence involving Suzuki-
Miyaura and EDC-promoted acylation coupling reactions was
competent to render chiral oxazolidinone analogues 16b, 16g, 18b,
18g and 23, with an ester functionality linking the oxazolidinone
and external aryl boronic fragments. Then, we converted the
external primary hydroxyl in 17 into the amine group of radezolid
intermediate 19 through a three-step sequence involving iodin-
ation followed by azidation and chemoselective hydrogenation.
Finally, the chiral analogues 20b and 20g featuring an amide link-
age between the oxazolidinone scaffold and the external aryl
boronic fragment, such in radezolid, were also prepared in a facile
manner by means of the EDC-promoted coupling of 19 with aryl
boronic acids 9b and 9g, respectively.
Scheme 2. Syntheses of racemic and chiral aryl boronic oxazolidinone derivatives. Reagents and conditions: (a) 4-(Hydroxymethyl)phenylboronic acid (1.4 equiv), K2CO3 (3 equiv),
Pd(PPh3)4 (0.05 equiv), PhMe/EtOH/H2O (4:1:1), reflux, 6 h, 90e95%; (b) Aryl carboxyl boronic acid 9a-f (1.05e2.0 equiv), EDCHCl (1.5e2.6 equiv), DMAP (0.4e1.0 equiv), DMF, rt,
24e96 h, 38e79%; (c) Isobutylamine (7e10 equiv), PhMe, 80e85 C, 14 h, 85%; (d) Ac2O (3.0 equiv), DMAP (0.05 equiv), Et3N (4 equiv), DCM, rt, 2 h, 88%; (e) NIS (1.1 equiv), TFA, rt,
2 h, 77%; (f) 3 or 4-substituted phenylboronic acid (1.4 equiv), K2CO3 (3 equiv), Pd(PPh3)4 (0.05 equiv), PhMe/EtOH/H2O (4:1:1), reflux, 6e10 h, 60e81%; (g) TBAF (1.2 equiv), THF,
0 C, 30 min, 68%; (h) PPh3 (2 equiv), imidazole (2.2 equiv), I2 (2.5 equiv), THF, rt, 10 min, 68%; (i) NaN3 (5.4 equiv), DMF, 70 C, 14 h, 96%; (j) Pd/C (10 % wt), H2 (1 bar), MeOH, rt, 2 h,
85%.
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Initially, the antibacterial activity of racemic aryl boronic oxa-
zolidinone analogues 10a-f was evaluated against the ESKAPE
panel of bacteria (for detailed information see the SI). All the3
compounds were additionally tested against wild-type E. coli ATCC
25922 and two E. coli mutant strains, JD17464 and JW5503. E. coli
JD17464 is a lpxC deletion mutant with impaired outer membrane,
while E. coli JW5503 is a tolC deletion mutant with defective efflux
pump. Additionally, we examined their antimicrobial activity
Table 1
Minimum inhibitory concentration (MIC) of racemic aryl boronic analogues against selected Gram-positive strains and E. coli JW5503, a tolC deletion mutant.
.
Compound MIC (mM)a Efflux ratiob
E. coli JW5503 E. faecalis 29212 VR E. faecalis 51575 E. faecium 35667 VR E. faecium 700221 S. aureus 29213 MR S. aureus 43300
LZD, 1 75 6.25 6.25 12.5 6.25 6.25 6.25 >1c
9b >50 >50 >50 >50 >50 >50 >50 ND
10a þ 9b >50 6.25 6.25 12.5 6.25 6.25 6.25 ND
10a >50 3.13 3.13 6.25 3.13 3.13 3.13 ND
10b 6.25 3.13 1.56 3.23 1.56 3.13 1.56 >8
10c 25 1.56 1.56 1.56 1.56 1.56 1.56 >2
10d 25 3.13 3.13 3.13 3.13 3.13 3.13 >2
10e 12.5 1.56 0.78 1.56 1.56 1.56 1.56 >4
10f 25 1.56 1.56 1.56 1.56 1.56 1.56 >2
a Minimum inhibitory concentrations (mM)were determined after 24 h incubation (n¼ 3). Ciprofloxacin was used as a positive control for E. coli JW5503 (Dtolc) at 0.02 mM,
and for both strains of E. faecalis and S. aureus at 3.0 and 1.5 mM, respectively. For E. faecium and VR E. faecium positive control LZD was used at 12 mM. VR ¼ vancomycin-
resistant; MR ¼ methicillin-resistant; LZD ¼ linezolid.
b Efflux ratio ¼ MIC E. coli 25922/MIC E. coli JW5503. ND: not determined for compounds with MIC >50 mM for both strains.
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vancomycin-resistant (VR) E. faecium and E. faecalis, as well as
methicillin-resistant (MR) S. aureus. The results of the antimicrobial
assays are presented as percentage of bacterial growth inhibition
(%) (Table S1). Overall, oxazolidinone analogues did not display
significant inhibition of GNB (e.g. inhibitions were<90%), except for
E. coli JW5503, which had similar results to GPB strains (90%),
excluding analogue 10a. In line with previous reports, [15g,k] these
results clearly indicate that bacterial efflux is the main phenome-
non associated with the low intracellular accumulation and poor
antimicrobial activity of NAOs against GNB.
Then, we sought to directly examine the relationship between
the pattern of substitution on the aryl boronic pharmacophore of
racemic oxazolidinone analogues 10a-f and their antimicrobial
potency against the GPB that initially had shown activity. Their
minimum inhibitory concentration (MIC) values are summarized
on Table 1. In general, all oxazolidinones equipped with a distal aryl
boronic acid 10b-10f exhibited lower MIC values than LZD that
ranged from a two-to an eight-fold decrease (e.g. 10e vs VR
E. faecalis 51575). In particular, 10b, that did not feature any sub-
stituent on the external aryl ring rather than the boronic acid, was
the analogue of this series showing a better balance of antibacterial
properties against all GPB isolates evaluated. Remarkably, 10b also
had the lowest MIC value against mutant GNB E. coli JW5503
(6.25 mM vs 75 mM for LZD), a result indicating that additional
substitution in the external aryl boronic ring is detrimental to
facilitate transport through GNB membranes, thus obstructing
intracellular accumulation.
Critically, control experiments firmly confirmed that (i) the
single 4-carboxylphenyl boronic acid compound 9b does not exert
any antimicrobial activity alone. Furthermore, (ii) the radezolid
scaffold is not responsible itself for the observed increase of anti-
microbial activity on GPB, even if analogue 10a generally displays
slightly lower MIC values than LZD, in fact those values are gener-
ally higher than those for aryl boronic oxazolidinone analogues
10b-f. Foremost, (iii) the presence of the boronic function on the
radezolid scaffold is the factor involved in the observed amplifi-
cation of antibacterial activity against GPB and mutant GNB strain
E. coli JW5503, since the simultaneous administration in a 1:1 ratio
of both compounds 9b (4-carboxylphenyl boronic acid) and 10a
(radezolid scaffold) does not reach the levels of antimicrobial4
inhibition displayed by 10b (radezolid scaffold that has the aryl
boronic ring linked by an ester functional group).
With these preliminary results in hand, we next proceeded to
evaluate the antimicrobial potency of the optimized series of chiral
oxazolidinones with distal aryl boronic pharmacophores. MIC
values are displayed on Table 2.
As it could be expected, the antimicrobial activity of all these
chiral analogues was much higher than all of their racemic coun-
terparts 10b-10f and LZD. For instance, the MIC values for the chiral
analogue 18b were between a two-fold (E. coli JW5503 and MR
S. aureus) and a four-fold lower (remainder of GPB strains) than the
respective values for its racemic counterpart 10b, which only differs
on the presence of enantiomers with both stereochemical config-
urations at C-5 (S and R).
Moreover, all these chiral analogues exhibited higher antimi-
crobial activities than their control parent compounds, which have
their terminal hydroxyl, phenol or amino protic group free before
the acylation coupling with the aryl boronic carboxyl compounds
9b and 9g. These results suggest that the observed activity of the
chiral oxazolidinone analogues does not arise as a result of meta-
bolic cleavage of their ester or amide linkage under physiological
conditions, a case inwhichwemay expect that the activities of both
control and acylated analogues are equal. Control compound 15 and
its chiral acylated analogue 16b constituted the exception to this
rule since the latter exhibited lack of antimicrobial activity for all
the GPB evaluated. We devise that such an effect can be ascribed to
the fact that the phenol scaffold 15 is relatively rigid compared to 17
and 19, and the aryl boronic fragment introduced on their acylated
analogues 16b and 16g lies on a different plane forming an angle
near 120 with respect to the rest of the molecule due to the
intrinsic sp2 trigonal geometry around the phenolic oxygen nuclei.
As such, the limited rotation around the phenolic bond imposes
molecules 16b and 16g to adopt rigid conformations far from the
linearity that enables oxazolidinones reach their active site on the
cavity of the ribosomal PTC.
Concerning the optimal position of the boronic acid group on the
distal aryl ring in relation to the acyl functional group linking it to the
rest of themolecule, the antimicrobial activity of analogues 16b and
16g against GPBwere low for comparison due to the rigidity of their
phenolic linkage (vide ante). However, we observed that in 18b and
18g, whereby the external aryl boronic ring is separated from the
Table 2
Minimum inhibitory concentration (MIC) of the chiral arylboronic acid analogue series against selected Gram-positive strains and E. coli JW5503, a tolC deletion mutant.
Compound MIC (mM) Efflux ratiob






LZD, 1 75 6.25 6.25 12.5 6.25 6.25 6.25 >1
15 (control) 1.56 0.39 0.39 0.78 0.39 0.78 0.78 >32
16b >50 >50 >50 >50 >50 >50 >50 ND
17 (control) 1.56 0.78 0.78 0.78 0.78 1.56 0.78 >32
18b 3.13 0.78 0.39 0.78 0.39 0.78 0.78 >16
18g 3.13 >50 0.78 >50 >50 1.56 0.78 >16
19 (control) 6.25 1.56 1.56 0.78 1.56 3.13 3.13 >8
20b 0.78 0.39 0.39 0.39 0.39 0.78 0.78 >64
20g 0.78 0.39 0.39 0.78 0.78 0.78 0.78 >64
22 (control) 3.13 1.56 3.13 1.56 1.56 3.13 1.56 >16
23 3.13 0.78 0.39 0.78 0.78 0.78 0.78 >16
aMinimum inhibitory concentrations (mM)were determined after 24 h incubation (n¼ 3). Ciprofloxacinwas used as a positive control for E. coli JW 5503 (Dtolc) at 0.02 mM, and
for both strains of E. faecalis and S. aureus at 3.0 and 1.5 mM, respectively. For E. faecium and VR E. faecium, LZD at 12 mM was used as positive control. VR ¼ vancomycin-
resistant; MR ¼ methicillin-resistant; LZD ¼ linezolid .
bEfflux ratio ¼ MIC E. coli 25922/MIC E. coli JW5503.ND: not determined for compounds with MIC >50 mM for both strains.
cCompound 15 is the control for analogues 16b and 16g; compound 17 is the control for 18b and 18g, compound 19 is the control for 20b and 20g, and 22 is the control for 23.
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fragment, para-is the optimal relationship between these two
functional groups on the external ring (18bvs18g). This difference in
antimicrobial activity ismore pronounced in the case of 18b and 18g
than between analogues 20b and 20g, in which the ester linkage is
replaced by an amide group although that para-relative disposition
remains optimal for 20b. We additionally observed that deviation of
the linearity in the relative conformation of the internal rings in
analogue 23 was also deleterious for the antimicrobial activity.
2.3. Physico-chemical properties
We thenperformed a quantitative structure-activity relationship
(QSAR) analysis to get insight into the physico-chemical profile of
this series of aryl-boronic-containing oxazolidinone analogues.
Table 3 summarizes themain calculated descriptors for the selected
chiral analogues 15e23 [7a,26]. In general, the amplified antimi-
crobial activity of compounds containing the aryl boronic fragment,
18b, 18g, 20b, 20g, 23, correlate with an increased lipophilicity
(clogD and AlogP) and a larger contribution to the quantitative es-
timate of the drug-likeness (QED ALOGP). In connection with pre-
vious reports, [15k] the only parameter that seems to correlate with
the augmented antimicrobial profile of20b and20g in relation to the
rest of the analogues, is their increased ability to engage in hydrogen5
bonding interactions due the presence of the amide linker. In this
sense, further computational studies are ongoing in our laboratories
to gain deeper insight into the fundamental questions concerning
the origin of the observed enhancement of antimicrobial activity
promoted by the installation of the aryl boronic fragment on the
external section of the oxazolidinone analogues.
3. Conclusion
To summarize, with all the data at hand we can conclude that
20b is the aryl boronic-containing oxazolidinone analogue with a
combination of structural features ensuring better antimicrobial
activities against the panel of clinically relevant GPB strains eval-
uated in this study. This may be attributed to the hydrogen bonding
acceptor character of the amide bond in 20b that may promote
additional interactions in the outer cavity of the ribosomal PTC
active site, combined with an optimal linear conformation with
freedom for the external aryl boronic ring to rotate and adapt to the
tight geometry of the PTC cavity. Compared to LZD, the amplified
antimicrobial activity observed in 20b varied between an eight-fold
for S. aureus 29213 andMR 43300 strains (MIC of 0.78 mM for 20b vs
6.25 mM for LZD), and a sixteen-fold to thirty-two-fold boost of
antimicrobial activity for the rest of GPB, including the VR strains of
E. faecalis and E. faecium. Remarkably, the antimicrobial activity
Table 3
Calculated physicochemical properties of the selected boronic analogues 15e23 using Discovery Studio 2019 (Accelrys Inc.).a
Name
R
cpKab cLogDc Rotatable Bonds ALogPd HBD Counte QED ALOGPf ES Sum ssNHg
LZD, 1 3.51;
4.88
0.89 4.00 0.89 1.00 0.75 2.61
15 3.85;
6.64
1.82 4.00 2.32 2.00 0.98 2.59
17 3.85 1.96 5.00 1.96 2.00 0.95 2.60
19 3.85;
6.8
1.58 5.00 1.67 2.00 0.91 2.61




















3.95 9.00 3.96 1.00 0.87 2.59
a The compounds were prepared for descriptors calculations using the LigPrep module (Schr€odinger LLC, USA) to produce a single, low-energy, 3D structure with correct
chiralities and then subjected to the calculations of descriptors within the QSAR module of Discovery Studio 2019 (Accelrys Inc.).
b Calculated pKa values.
c Compound/Fragment octanol: aqueous buffer (at pH 7.4) distribution coefficient.
d Atomic contribution to the logP, octanol:water partition coefficient.
e Hydrogen bond donors count.
f ALOGP contribution to the Quantitative Estimate of Drug-Likeness.
g Electrotopological state descriptor of NH with two single bonds.
C.D. Cruz, P. Wrigstedt, K. Moslova et al. European Journal of Medicinal Chemistry 211 (2021) 113002reached a near one hundred-fold level of amplification for 20b and
20g in relation to LZD and a four-fold increase in relation to the rest
of chiral analogues 18b, 18g, and 23, against the mutant GNB strain
E. coli JW5503 with defective efflux pump (MIC of 0.78 mM for 20b
vs > 50 mM for LZD, and 3.13 mM for 18b, 18g, and 23). Our results
strongly suggest that the introduction of pharmacophores with
Lewis character, such as aryl boronic acids into the peripheral
section of oxazolidinone molecules with a linker capable of
engaging in hydrogen bonding interactions such an amide group,
and a linear but flexible conformation, may be a promising com-
bination of structural features to expand the antimicrobial spec-
trum of oxazolidinone analogues and render them active against
GNB bacteria. Further research is undergoing in our laboratories to
reach this goal by overcoming the obstacle of efflux pumps and
gaining further insight into the molecular basis of the observed
antimicrobial activities.
Author contribution
C. D. C. Designed, conducted and supervised the antimicrobial
evaluation of the compounds in this study. Contributed to the
manuscript preparation. P.W. Assisted on the design and developed
the syntheses of the compounds in this study. Contributed on the
manuscript preparation. K. M. Conducted the Elemental and HRMS
analyses and assisted to the chiral determination of the compounds
in this study. V. I. Assisted on the syntheses of the compounds in6
this study. H. M. Assisted on the antimicrobial evaluation of the
compounds in this study. L. G. Designed and conducted the calcu-
lation of the physicochemical properties for the compounds in this
study. S. H. Assisted on the NMR structural determination of the
compounds in this study. P. T. Contributed to design and supervised
the antimicrobial evaluation of the compounds in this study.
Contributed to manuscript preparation. J. P. B. Designed the syn-
theses of the compounds in this study, and wrote the manuscript.
All authors have read, participated and approve this manuscript.Declaration of competing interest
The authors declare that they have no known competing
financial interests or personal relationships that could have
appeared to influence the work reported in this paper.Acknowledgements
The Academy of Finland is thanked for supporting this project
(Consortium NO-ESCAPE, decisions no. 321551 and 321778). The
Helsinki Institute of Life Science (HiLife), and the Faculty of Science
of the University of Helsinki are also acknowledged for supporting
this project. L.G. gratefully acknowledges the support of the Drug
Discovery and Chemical Biology Network of Biocenter Finland and
the CSC for computational resources.
C.D. Cruz, P. Wrigstedt, K. Moslova et al. European Journal of Medicinal Chemistry 211 (2021) 113002Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.ejmech.2020.113002.
References
[1] (a) C.W. Murray, D.C. Rees, The rise of fragment-based drug discovery, Nat.
Chem. 1 (2009) 187e192;
(b) D.A. Erlanson, S.W. Fesik, R.E. Hubbard, W. Jahnke, H. Jhoti, Twenty years
on: the impact of fragments on drug discovery, Nat. Rev. Drug Discov. 15
(2016) 605e619;
(c) R. Santos, et al., A comprehensive map of molecular drug targets, Nat. Rev.
Drug Discov. 16 (2017) 19e34.
[2] (a) M.A. Fischbach, C.T. Walsh, Antibiotics for emerging pathogens, Science
325 (2009) 1089e1093;
(b) K.J. Simmons, I. Chopra, C.W.G. Fishwick, Structure-based discovery of
antibacterial drugs, Nat. Rev. Microbiol. 8 (2010) 501e510;
(c) K. Lewis, Platforms for antibiotic discovery, Nat. Rev. Drug Discov. 12
(2013) 371e387;
(d) R. Cain, S. Narramore, M. McPhillie, K. Simmons, C.W.G. Fishwick, Appli-
cations of structure-based design to antibacterial drug discovery, Bioorg.
Chem. 55 (2014) 69e76;
(e) J.A. Jones, K.G. Virga, G. Gumina, K.E. Hevener, Recent advances in the
rational design and optimization of antibacterial agents, Med. Chem. Com-
mun. 7 (2016) 1694e1715.
[3] (a) S.B. Levy, B. Marshall, Antibacterial resistance worldwide: causes, chal-
lenges and responses, Nat. Med. 10 (2004) S122eS129;
(b) J.F. Fisher, S. Mobashery, Endless resistance. Endless antibiotics? Med.
Chem. Commun. 7 (2016) 37e49;
(c) M.F. Chellat, L. Raguz, R. Riedl, Targeting antibiotic resistance, Angew.
Chem. Int. Ed. 55 (2016) 6600e6626.(d) World Health Organization Antimi-
crobial Resistance: Fact Sheets: 2017 and January 2018.
[4] (a) C. Årdal, et al., To the G20: incetivising antibacterial research and develop-
ment, Lancet Infect. Dis. 17 (2017) 799e801;
(b) V.L. Simpkin, M.J. Renwick, R. Kelly, E. Mossialos, Incetivising innovation in
antibiotic drug discovery and development: progress, challenges and next
steps, J. Antibiot. 70 (2017) 1087e1096;
(c) M. Renwick, E. Mossialos, What are the economic barriers of antibiotic R&D
andhowcanweovercome them?ExpertOpin.DrugDiscov. 13 (2018) 889e892.
[5] (a) B. Spellberg, K.A. Marr, E.P. Brass, Regulatory pathways for new antimi-
crobial agents: trade-offs to keep the perfect from being the enemy of the
good, Clin. Pharmacol. Ther. 100 (2016) 597e599;
(b) D.M. Shlaes, Research and development of antibiotics: the next battle-
ground, ACS Infect. Dis. 1 (2015) 232e233.
[6] (a) M.N. Gwynn, A. Portnoy, S.F. Rittenhouse, D.J. Payne, Challenges of anti-
bacterial discovery revisited, Ann. N. Y. Acad. Sci. 1213 (2010) 5e19;
(b) R. Laxminarayan, P. Matsoso, S. Pant, C. Brower, J.-A. Rottingen,
K. Klugman, S. Davies, Access to effective antimicrobials: a worldwide chal-
lenge, Lancet 387 (2016) 168e175;
(c) S.B. Singh, K. Young, L.L. Silver, What is an “ideal” antibiotic? Discovery
challenges and path forward, Biochem. Pharmacol. 133 (2017) 63e73.
[7] (a) R. O’Shea, H.E. Moser, Physicochemical properties of antibacterial com-
pounds: implications for drug discovery, J. Med. Chem. 51 (2008) 2871e2878;
(b) A.C. Pawlowski, J.W. Johnson, G.D. Wright, Evolving medicinal chemistry
strategies in antibiotic discovery, Curr. Opin. Biotechnol. 42 (2016) 108e117;
(c) M.F. Richter, et al., Predictive compound accumulation rules yield a broad-
spectrum antibiotic, Nature 545 (2017) 299e304;
(d) R. Tommasi, R. Iyer, A.A. Miller, Antibacterial drug discovery: some as-
sembly required, ACS Infect. Dis. 4 (2018) 686e695;
(e) R.J. Young, P.D. Leeson, Mapping the efficiency and physicochemical tra-
jectories of successful optimizations, J. Med. Chem. 61 (2018) 6421e6467.
[8] M.F. Richter, P.J. Hergenrother, The challenge of converting Gram-positive-
only compounds into broad-spectrum antibiotics, Ann. N. Y. Acad. Sci. 1435
(2019) 18e38.
[9] (a) C. Ford, G. Zurenko, M. Barbachyn, The discovery of linezolid, the first
oxazolidinone antibacterial agent, Curr. Drug Target -infectious Disord. 1
(2001) 181e199;
(b) D.J. Diekema, R.N. Jones, Oxazolidinone antibiotics, Lancet 358 (2001)
1975e1982;
(c) K.J. Shaw, M.R. Barbachyn, The oxazolidinones: past, present, and future:
the oxazolidinones: past, present, and future, Ann Ny Acad Sci 1241 (2011)
48e70.
[10] (a) S.M. Swaney, H. Aoki, M.C. Ganoza, D.L. Shinabarger, The oxazolidinone
linezolid inhibits initiation of protein synthesis in bacteria, Antimicrob. Agents
Chemother. 42 (1998) 3251e3255;
(b) D.L. Shinabarger, Mechanism of action of the oxazolidinone antibacterial
agents, Expet Opin. Invest. Drugs 8 (1999) 1195e1202;
(c) K.L. Leach, et al., The site of action of oxazolidinone antibiotics in living
bacteria and in human mitochondria, Mol. Cell. 26 (2007) 393e402.
[11] (a) J.A. Ippolito, et al., Crystal structure of the oxazolidinone antibiotic line-
zolid bound to the 50S ribosomal subunit k, J. Med. Chem. 51 (2008)
3353e3356;7
(b) D.N. Wilson, F. Schluenzen, J.M. Harms, A.L. Starosta, S.R. Connell, P. Fucini,
The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase
center and effect TRNA positioning, Proc. Nat. Acad. Sci.USA 105 (2008)
13339e13344.
[12] (a) M.R. Barbachyn, C.W. Ford, Oxazolidinone structureeactivity relationships
leading to linezolid, Angew. Chem. Int. Ed. 42 (2003) 2010e2023;
(b) D. Hutchinson, Oxazolidinone antibacterial agents: a critical review, Curr.
Top. Med. Chem. 3 (2003) 1021e1042;
(c) A.R. Renslo, G.W. Luehr, M.F. Gordeev, Recent developments in the iden-
tification of novel oxazolidinone antibacterial agents, Bioorg. Med. Chem. 14
(2006) 4227e4240.
[13] (a) D.L. Stevens, D. Herr, H. Lampiris, J.L. Hunt, D.H. Batts, B. Hafkin, Linezolid
versus vancomycin for the treatment of methicillin-resistant Staphylococcus
aureus infections, Clin. Infect. Dis. 34 (2002) 1481e1490;
(b) R.N. Jones, et al., Zyvox® annual appraisal of potency and spectrum pro-
gram: linezolid surveillance program results for 2008, Diagn. Microbiol. Infect.
Dis. 65 (2009) 404e413;
(c) K.S. Long, B. Vester, Resistance to linezolid caused by modifications at its
binding site on the ribosome, Antimicrob. Agents Chemother. 56 (2012)
603e612;
(d) L.M. Deshpande, M. Castanheira, R.K. Flamm, R.E. Mendes, Evolving oxa-
zolidinone resistance mechanisms in a worldwide collection of enterococcal
clinical isolates: results from the SENTRY antimicrobial surveillance program,
J. Antimicrob. Chemother. 73 (2018) 2314e2322.
[14] P.M. Wright, I.B. Seiple, A.G. Myers, The evolving role of chemical synthesis in
antibacterial drug discovery, Angew. Chem. Int. Ed. 53 (2014) 8840e8869.
[15] (a) S.J. Brickner, et al., Synthesis and antibacterial activity of U-100592 and U-
100766, two oxazolidinone antibacterial agents for the potential treatment of
multidrug-resistant gram-positive bacterial infections, J. Med. Chem. 39
(1996) 673e679;
(b) S.D. Paget, et al., Synthesis and antibacterial activity of pyrroloaryl-
substituted oxazolidinones, Bioorg. Med. Chem. Lett 13 (2003) 4173e4177;
(c) J. Zhou, et al., Design at the atomic level: design of biaryloxazolidinones as
potent orally active antibiotics, Bioorg. Med. Chem. Lett 18 (2008)
6175e6178;
(d) E. Skripkin, T.S. McConnell, J. DeVito, L. Lawrence, J.A. Ippolito, E.M. Duffy,
J. Sutcliffe, F.R. Franceschi, Chi-01, a new family of oxazolidinones that over-
come ribosome-based linezolid resistance, Antimicrob. Agents Chemother. 52
(2008) 3550e3557;
(e) W.B. Im, S.H. Choi, J.-Y. Park, S.H. Choi, J. Finn, S.-H. Yoon, Discovery of
torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent, Eur.
J. Med. Chem. 46 (2011) 1027e1039;
(f) H. Suzuki, I. Utsunomiya, K. Shudo, N. Fukuhara, T. Iwaki, T. Yasukata,
Synthesis and in vitro/in vivo antibacterial activity of oxazolidinones having
thiocarbamate at C-5 on the A-ring and an amide- or urea-substituted [1,2,5]
Triazepane or [1,2,5]Oxadiazepane as the C-ring, Eur. J. Med. Chem. 69 (2013)
262e277;
(g) M.F. Gordeev, Z.Y. Yuan, New potent antibacterial oxazolidinone (MRX-I)
with an improved class safety profile, J. Med. Chem. 57 (2014) 4487e4497;
(h) C.G. Fortuna, et al., New potent antibacterials against gram-positive
multiresistant pathogens: effects of side chain modification and chirality in
linezolid-like 1,2,4-oxadiazoles, Bioorg. Med. Chem. 22 (2014) 6814e6825;
(i) T. Yang, et al., Discovery of a teraryl oxazolidinone compound (S)-N-((3-(3-
Fluoro-4-(4-(Pyridin-2-Yl)-1H-Pyrazol-1-Yl)Phenyl)-2-Oxooxazolidin-5-Yl)
Methyl)Acetamide phosphate as a novel antimicrobial agent with enhanced
safety profile and efficacies, J. Med. Chem. 58 (2015) 6389e6409;
(j) K. Takrouri, et al., Progress against Escherichia coli with the oxazolidinone
class of antibacterials: test case for a general approach to improving whole-
cell gram-negative activity, ACS Infect. Dis. 2 (2016) 405e426;
(k) A. Spaulding, et al., Compound design guidelines for evading the efflux and
permeation barriers of Escherichia coli with the oxazolidinone class of anti-
bacterials: test case for a general approach to improving whole cell gram-
negative activity, Bioorg. Med. Chem. Lett 27 (2017) 5310e5321;
(l) M.S. Deshmukh, N. Jain, Design, synthesis, and antibacterial evaluation of
oxazolidinones with fused heterocyclic C-ring substructure, ACS Med. Chem.
Lett. 8 (2017) 1153e1158;
(m) H. Zhao, et al., Discovery of fluorine-containing benzoxazinyl-oxazolidi-
nones for the treatment of multidrug resistant tuberculosis, ACS Med. Chem.
Lett. 8 (2017) 533e537;
(n) A. Ramírez-Villalva, et al., Synthesis and antifungal activity of novel oxa-
zolidin-2-one-linked 1,2,3-triazole derivatives, Med. Chem. Commun. 8
(2017) 2258e2262;
(o) Y. Wu, et al., Design and synthesis of biaryloxazolidinone derivatives
containing a rhodanine or thiohydantoin moiety as novel antibacterial agents
against gram-positive bacteria, Bioorg. Med. Chem. Lett 29 (2018) 496e502;
(p) Y. Hou, et al., Synthesis and antibacterial evaluation of novel oxazolidinone
derivatives containing a piperidinyl moiety, Bioorg. Med. Chem. Lett 29 (2019)
126746.
[16] (a) R. Smoum, A. Rubinstein, V.M. Dembitsky, M. Srebnik, Boron containing
compounds as protease inhibitors, Chem. Rev. 112 (2012) 4156e4220;
(b) G.F.S. Fernandes, W.A. Denny, J.L.D. Santos, Boron in drug design: recent
advances in the development of new therapeutic agents, Eur. J. Med. Chem.
179 (2019) 791e804;
(c) J. Plescia, N. Moitessier, Design and discovery of boronic acid drugs, Eur. J.
Med. Chem. 195 (2020) 112270.
C.D. Cruz, P. Wrigstedt, K. Moslova et al. European Journal of Medicinal Chemistry 211 (2021) 113002[17] A. Krajnc, P.A. Lang, T.D. Panduwawala, J. Brem, C.J. Schofield, Will morphing
boron-based inhibitors beat the b-lactamases? Curr. Opin. Chem. Biol. 50
(2019) 101e110.
[18] V.M. Dembitsky, A.A.A.A. Quntar, M. Srebnik, Natural and synthetic small
boron-containing molecules as potential inhibitors of bacterial and fungal
quorum sensing, Chem. Rev. 111 (2011) 209e237.
[19] F. Fontaine, A. Hequet, A.-S. Voisin-Chiret, A. Bouillon, A. Lesnard, T. Cresteil,
C. Jolivalt, S. Rault, First identification of boronic species as novel potential
inhibitors of the Staphylococcus aureus NorA efflux pump, J. Med. Chem. 57
(2014) 2536e2548.
[20] L. Lawrence, P. Danese, J. DeVito, F. Franceschi, J. Sutcliffe, Vitro activities of
the rx-01 oxazolidinones against hospital and community pathogens, Anti-
microb. Agents Chemother. 52 (2008) 1653e1662.
[21] (a) W. Mahy, J.A. Leitch, C.G. Frost, Copper catalyzed assembly of N-arylox-
azolidinones: synthesis of linezolid, tedizolid, and rivaroxaban, Eur. J. Org
Chem. (2016) 1305e1313.(b) Oyelere, A.K.; Goldberg, J.A.; Orbin, A.; Salvino,
J.M.; Zhou, J. Biaryl Heterocyclic Amines, Amides and Sulfur-Containing
Compounds and Methods of Making and Using the Same. PCT WO 2005/
012270 A2.
[22] (a) M.T. Sabatini, L.T. Boulton, T.D. Sheppard, Borate esters: simple catalysts8
for the sustainable synthesis of complex amides, Sci. Adv. 3 (2017), e1701028;
(b) S. Arkhipenko, et al., Mechanistic insights into boron-catalysed direct
amidation reactions, Chem. Sci. 9 (2018) 1058e1072.
[23] A.L. Korich, P.M. Iovine, Dalton Trans. 39 (2010) 1423e1431.
[24] (a) W.R. Perrault, et al., The synthesis of N-Aryl-5(S)-Aminomethyl-2-
Oxazolidinone antibacterials and derivatives in one step from aryl carba-
mates, Org. Process Res. Dev. 7 (2003) 533e546;
(b) A.W. Sun, et al., Incorporation of a chiral gem-disubstituted nitrogen
heterocycle yields an oxazolidinone antibiotic with reduced mitochondrial
toxicity, Bioorg. Med. Chem. Lett 29 (2019) 2686e2689.
[25] (a) Berzosa Rodriguez, X.; Marquillas Olondriz, F; Llebaria Soldevilla, A; Serra
Comas, C. Process for obtaining rivaroxaban and intermediate thereof. PCT
WO 2012/159992 A1; (b) M. Ciaccia, R. Cacciapaglia, P. Mencarelli,
L. Mandolini, S. Di Stefano, Fast transimination in organic solvents in the
absence of proton and metal catalysts. A key to iminemetathesis catalyzed by
primary amines under mild conditions, Chem. Sci. 4 (2013) 2253e2261.
[26] N.K. Litterman, C.A. Lipinski, B.A. Bunin, S. Ekins, Computational prediction
and validation of an expert’s evaluation of chemical probes, J. Chem. Inf.
Model. 54 (2014) 2996e3004.
